AN2 Therapeutics clinical trials we track

Check company identity source

Phase 2 / 3 1 trial

TrialDrugs studiedStatusPrimary completion
Study of Epetraborole in Patients With Treatment-refractory MAC Lung DiseaseNCT05327803EpetraboroleTerminated2024-12-18Actual

Phase 2 1 trial

TrialDrugs studiedStatusPrimary completion
Phase 2 Study of Oral Epetraborole in Adults With Polycythemia VeraNCT07891533EpetraboroleNot yet recruiting2029-04Estimated

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Phase 2: Assessment of Novel Patient Reported Outcome Instrument Psychometric Properties Measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole Measure: Phase 2: Percentage of Participants Achieving Clinical Response Measure: Phase 3: Percentage of Participants Achieving Clinical Response. After: Measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole Measure: Phase 2: Percentage of Participants Achieving Clinical Response Measure: Phase 3: Percentage of Participants Achieving Clinical Response.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Phase 2: Assessment of novel Patient Reported Outcome instrument psychometric properties Measure: Phase 2: Percentage of Participants Achieving Clinical Response Measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole Measure: Phase 3: Percentage of Participants Achieving Clinical Response. After: Measure: Phase 2: Assessment of Novel Patient Reported Outcome Instrument Psychometric Properties Measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole Measure: Phase 2: Percentage of Participants Achieving Clinical Response Measure: Phase 3: Percentage of Participants Achieving Clinical Response.

Check registry source